Vaxcyte Inc

Latest Results (13.11.2025):

Vaxcyte Inc’s second quarter 2025 report highlights the company’s robust financial position, with approximately $2.8 billion in cash, cash equivalents, and investments as of June 30, 2025, alongside significant clinical and regulatory progress in its PCV (pneumococcal conjugate vaccine) programs. The report details ongoing developments in both adult and pediatric indications for VAX-31, and outlines strategic capital allocation and pipeline streamlining initiatives to support its future growth.

Strong Financial Position

The company reported a solid balance sheet with approximately $2.8 billion in liquidity as of the end of Q2 2025. This financial strength supports Vaxcyte Inc’s disciplined approach toward capital allocation and positions it well for advancing its PCV program initiatives.

Advancements in VAX-31 Adult Program

Following key interactions with the FDA, including an End-of-Phase 2 meeting, Vaxcyte Inc is finalizing its Phase 3 clinical program for the VAX-31 adult indication. The pivotal non-inferiority study is expected to start in Q4 2025, with topline data anticipated in 2026, setting the stage for subsequent Phase 3 data readouts in 2026 and 2027.

Updates in VAX-31 Pediatric Program

The ongoing Phase 2 dose-finding study for the pediatric indication has been modified to include an optimized dose arm, while discontinuing the low dose arm. Enrollment in the study is set to continue through the end of Q3 2025, with primary and booster dose data expected by the first half of 2027.

Strategic Pipeline Prioritization

Vaxcyte Inc is streamlining its early-stage pipeline to prioritize resource allocation toward its leading PCV franchise. This includes pausing further advancement of select candidates beyond the preclinical stage, a move designed to deepen focus on the VAX-31 programs while preserving options for future asset development.